The impact of comorbidity on treatment (chemoradiation and laryngectomy) of advanced, nondistant metastatic laryngeal cancer: A review of 16 849 cases from the National Cancer Database (2003-2008)

Archives of Otolaryngology - Head and Neck Surgery

Volumn 138, Issue 12, 2012, Pages 1120-1128

  Zhu, Jason ^b   Fedewa, Stacey ^a   Chen, Amy Y ^b  

^a AMERICAN CANCER SOCIETY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; CANCER RADIOTHERAPY; CANCER SURGERY; CHARLSON DEYO COMORBIDITY INDEX SCORE; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT TOOL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FEMALE; HEALTH INSURANCE; HIGH SCHOOL GRADUATE; HUMAN; LARYNGECTOMY; LARYNX METASTASIS; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBSERVATIONAL STUDY; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SOCIOECONOMICS; WASHINGTON UNIVERSITY HEAD AND NECK COMORBIDITY INDEX SCORE;

EID: 84872057713     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/jamaoto.2013.720     Document Type: Review

References (44)

1. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer. 2000;88(3):653-663. (Pubitemid 30056943)
2. Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(1):22-30.
3. Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885-892. (Pubitemid 32171549)
4. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol. 2004;57 (6):597-609. (Pubitemid 38891497)
5. Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005;97(1):104-109. (Pubitemid 40403681)
6. Tetsche MS, Nørgaard M, Jacobsen J, Wogelius P, Sørensen HT. Comorbidity and ovarian cancer survival in Denmark, 1995-2005: a population-based cohort study. Int J Gynecol Cancer. 2008;18(3):421-427. (Pubitemid 351668304)
7. De Marco MF, Janssen-Heijnen ML, van der Heijden LH, Coebergh JW. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000;36(1):95-99. (Pubitemid 30035350)
8. Brooks SE, Chen TT, Ghosh A, Mullins CD, Gardner JF, Baquet CR. Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix. Gynecol Oncol. 2000;79(1):107-115.
9. Janssen-Heijnen ML, Maas HA, Lemmens VE, et al. The correlation of age and comorbidity with therapy and survival in cancer patients in North-Brabant and North-Limburg, 1995-2001. Ned Tijdschr Geneeskd. 2005;149(30):1686-1690. (Pubitemid 41167781)
10. Payne JE, Meyer H-J. The influence of other diseases upon the outcome of colorectal cancer patients. Aust N Z J Surg. 1995;65(6):398-402.
11. Rieker RJ, Hammer E, Eisele R, Schmid E, Högel J. The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbecks Arch Surg. 2002;387(2):72-76. (Pubitemid 36061886)
12. Fisher DA, Galanko J, Dudley TK, Shaheen NJ. Impact of comorbidity on colorectal cancer screening in the veterans healthcare system. Clin Gastroenterol Hepatol. 2007;5(8):991-996. (Pubitemid 47127025)
13. van der Aa MA, Siesling S, Kruitwagen RF, Lybeert ML, Coebergh JW, Janssen- Heijnen ML. Comorbidity and age affect treatment policy for cervical cancer: a population-based study in the south of the Netherlands, 1995-2004. Eur J Gynaecol Oncol. 2008;29(5):493-498.
14. Derks W, de Leeuw RJ, Hordijk GJ. Elderly patients with head and neck cancer: the influence of comorbidity on choice of therapy, complication rate, and survival. Curr Opin Otolaryngol Head Neck Surg. 2005;13(2):92-96. (Pubitemid 40388250)
15. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110(4):593-602. (Pubitemid 30198711)
16. Chen AY, Matson LK, Roberts D, Goepfert H. The significance of comorbidity in advanced laryngeal cancer. Head Neck. 2001;23(7):566-572. (Pubitemid 32565530)
17. Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998;20 (1):1-7.
18. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer. 1996;77(5):834-842. (Pubitemid 26061274)
19. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-2098. (Pubitemid 37464533)
20. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1270-1276. (Pubitemid 350294258)
21. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006; 116(9, pt 2)(suppl 111):1-13. (Pubitemid 44337830)
22. American College of Surgeons. National Cancer Data Base (NCDB). http://www.facs.org/cancer/ncdb/index.html. Accessed March 16, 2011.
23. Commission on Cancer . Facility Oncology Registry Data Standards (FORDS). Chicago, IL: American College of Surgeons; 2007.
24. Greene FL; American Joint Committee on Cancer; American Cancer Society. Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
26. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg. 2002; 128(10):1172-1179.
27. Piccirillo JF, Spitznagel EL Jr, Vermani N, Costas I, Schnitzler M. Comparison of comorbidity indices for patients with head and neck cancer. Med Care. 2004; 42(5):482-486.
28. Deddens JA, Petersen MR. Approaches for estimating prevalence ratios. Occup Environ Med. 2008;65(7):481, 501-506.
29. Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92(8):2109-2116. (Pubitemid 32973321)
30. Alho O-P, Hannula K, Luokkala A, Teppo H, Koivunen P, Kantola S. Differential prognostic impact of comorbidity in head and neck cancer. Head Neck. 2007; 29(10):913-918.
31. Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997;107(11, pt 1):1469-1475. (Pubitemid 27481468)
32. Howlader NNA, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
33. McGuirt WF, Davis SP III. Demographic portrayal and outcome analysis of head and neck cancer surgery in the elderly. Arch Otolaryngol Head Neck Surg. 1995; 121(2):150-154.
34. Ferrier MB, Spuesens EB, Le Cessie S, Baatenburg de Jong RJ. Comorbidity as a major risk factor for mortality and complications in head and neck surgery. Arch Otolaryngol Head Neck Surg. 2005;131(1):27-32.
35. Chen AY, Schrag N, Hao Y, et al. Changes in treatment of advanced laryngeal cancer 1985-2001. Otolaryngol Head Neck Surg. 2006;135(6):831-837. (Pubitemid 44820630)
36. Borggreven PA, Kuik DJ, Quak JJ, de Bree R, Snow GB, Leemans CR. Comorbid condition as a prognostic factor for complications in major surgery of the oral cavity and oropharynx with microvascular soft tissue reconstruction. Head Neck. 2003;25(10):808-815. (Pubitemid 37139893)
37. Suh JD, Sercarz JA, Abemayor E, et al. Analysis of outcome and complications in 400 cases of microvascular head and neck reconstruction. Arch Otolaryngol Head Neck Surg. 2004;130(8):962-966. (Pubitemid 39045604)
38. Chen AY, Fedewa S, Zhu J. Temporal trends in the treatment of early- and advancedstage laryngeal cancer in the United States, 1985-2007. Arch Otolaryngol Head Neck Surg. 2011;137(10):1017-1024.
39. Guidry JJ, Aday LA, Zhang D, Winn RJ. Transportation as a barrier to cancer treatment. Cancer Pract. 1997;5(6):361-366. (Pubitemid 28078000)
40. Shavers VL, Harlan LC, Winn D, Davis WW. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer Metastasis Rev. 2003;22(1):25-38. (Pubitemid 36363511)
41. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. Med Care. 2006;44(10):921-928. (Pubitemid 44454569)
42. Robbins AS, Lin AC, Virgo KS. Comparison of Comorbid Medical Conditions among Elderly Colorectal Cancer Patients in the National Cancer Data Base and the SEERMedicare Data Base. Portland, OR: North American Association of Central Cancer Registries; 2012.
43. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20): 2441-2447. (Pubitemid 38669187)
44. Johnston AS, Piccirillo JF, Creech C, Littenberg B, Jeffe D, Spitznagel EL. Validation of a comorbidity education program. J Reg Manag. 2001;28(3):125-131.